Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?

Anna Forsythe,1 David Chandiwana,2 Janina Barth,3 Marroon Thabane,4 Johan Baeck,5 Anastasiya Shor,1 Gabriel Tremblay6 1Health Technology Assessment Evidence, Purple Squirrel Economics, New York, NY, USA; 2Global Value and Access, Novartis Pharmaceutical Corporation, East Hanover, NJ, USA; 3German Ma...

Full description

Bibliographic Details
Main Authors: Forsythe A, Chandiwana D, Barth J, Thabane M, Baeck J, Shor A, Tremblay G
Format: Article
Language:English
Published: Dove Medical Press 2018-05-01
Series:Cancer Management and Research
Subjects:
Breast cancer
overall survival
progression-free survival
health-related quality of life
systematic literature review
Online Access:https://www.dovepress.com/is-progression-free-survival-a-more-relevant-endpoint-than-overall-sur-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/is-progression-free-survival-a-more-relevant-endpoint-than-overall-sur-peer-reviewed-article-CMAR

Similar Items